These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 39042770)
1. Efficacy and Safety of Bleselumab in Preventing the Recurrence of Primary Focal Segmental Glomerulosclerosis in Kidney Transplant Recipients: A Phase 2a, Randomized, Multicenter Study. Shoji J; Goggins WC; Wellen JR; Cunningham PN; Johnston O; Chang SS; Solez K; Santos V; Larson TJ; Takeuchi M; Wang X Transplantation; 2024 Aug; 108(8):1782-1792. PubMed ID: 39042770 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study. Harland RC; Klintmalm G; Jensik S; Yang H; Bromberg J; Holman J; Kumar MSA; Santos V; Larson TJ; Wang X Am J Transplant; 2020 Jan; 20(1):159-171. PubMed ID: 31509331 [TBL] [Abstract][Full Text] [Related]
3. A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti-CD40 monoclonal antibody, in kidney transplantation. Vincenti F; Klintmalm G; Yang H; Ram Peddi V; Blahunka P; Conkle A; Santos V; Holman J Am J Transplant; 2020 Jan; 20(1):172-180. PubMed ID: 31397943 [TBL] [Abstract][Full Text] [Related]
4. Focal segmental glomerulosclerosis in pediatric kidney transplantation: 30 years' experience. Cleper R; Krause I; Bar Nathan N; Mor M; Dagan A; Weissman I; Frishberg Y; Rachamimov R; Mor E; Davidovits M Clin Transplant; 2016 Oct; 30(10):1324-1331. PubMed ID: 27490751 [TBL] [Abstract][Full Text] [Related]
5. A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Delville M; Sigdel TK; Wei C; Li J; Hsieh SC; Fornoni A; Burke GW; Bruneval P; Naesens M; Jackson A; Alachkar N; Canaud G; Legendre C; Anglicheau D; Reiser J; Sarwal MM Sci Transl Med; 2014 Oct; 6(256):256ra136. PubMed ID: 25273097 [TBL] [Abstract][Full Text] [Related]
6. Long-Term Outcome of Kidney Transplantation in Recipients with Focal Segmental Glomerulosclerosis. Francis A; Trnka P; McTaggart SJ Clin J Am Soc Nephrol; 2016 Nov; 11(11):2041-2046. PubMed ID: 27797890 [TBL] [Abstract][Full Text] [Related]
7. Successful Preemptive Kidney Transplantation With Rituximab Induction in a Patient With Focal Segmental Glomerulosclerosis and Massive Nephrotic Syndrome: A Case Report. Kolonko A; Piecha G; Więcek A Transplant Proc; 2016 Nov; 48(9):3092-3094. PubMed ID: 27932154 [TBL] [Abstract][Full Text] [Related]
8. Mortality and Allograft Loss Trends Among US Pediatric Kidney Transplant Recipients With and Without Focal Segmental Glomerulosclerosis. Wang CS; Gander J; Patzer RE; Greenbaum LA Am J Kidney Dis; 2018 Mar; 71(3):392-398. PubMed ID: 29277509 [TBL] [Abstract][Full Text] [Related]
9. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280 [TBL] [Abstract][Full Text] [Related]
10. Angiotensin II receptor 1 antibodies associate with post-transplant focal segmental glomerulosclerosis and proteinuria. Abuzeineh M; Aala A; Alasfar S; Alachkar N BMC Nephrol; 2020 Jul; 21(1):253. PubMed ID: 32615995 [TBL] [Abstract][Full Text] [Related]
11. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial. Krämer BK; Klinger M; Vítko Š; Glyda M; Midtvedt K; Stefoni S; Citterio F; Pietruck F; Squifflet JP; Segoloni G; Krüger B; Sperschneider H; Banas B; Bäckman L; Weber M; Carmellini M; Perner F; Claesson K; Marcinkowski W; Ostrowski M; Senatorski G; Nordström J; Salmela K Transplantation; 2012 Sep; 94(5):492-8. PubMed ID: 22858806 [TBL] [Abstract][Full Text] [Related]
12. The impact of mycophenolate mofetil versus azathioprine as adjunctive therapy to cyclosporine on the rates of renal allograft loss due to glomerular disease recurrence. Pham PT; Pham PC Nephrol Dial Transplant; 2012 Jul; 27(7):2965-71. PubMed ID: 22207327 [TBL] [Abstract][Full Text] [Related]
14. Pilot Randomized Trial of Tacrolimus/Everolimus vs Tacrolimus/Enteric-Coated Mycophenolate Sodium in Adult, Primary Kidney Transplant Recipients at a Single Center. Ciancio G; Tryphonopoulos P; Gaynor JJ; Guerra G; Sageshima J; Roth D; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Hanson L; Powell RH; Ruiz P; Vianna R; Burke GW Transplant Proc; 2016; 48(6):2006-10. PubMed ID: 27569936 [TBL] [Abstract][Full Text] [Related]
15. Recurrent and De Novo Focal Segmental Glomerulosclerosis After Kidney Transplantation: Comparison of Clinical Features and Transplant Outcomes. Kim DK; Huh H; Kim Y; Kim T; Kim YH; Choi BH; Lee HJ; Kang MS; Kim SR; Lee DW; Lee SB; Kim IY Transplant Proc; 2024 Oct; 56(8):1752-1756. PubMed ID: 39232925 [TBL] [Abstract][Full Text] [Related]
16. A Prospective Randomized, Comparative Trial of High-Dose Mizoribine Versus Mycophenolate Mofetil in Combination With Tacrolimus and Basiliximab for Living Donor Renal Transplant: A Multicenter Trial. Ishida H; Takahara S; Amada N; Tomikawa S; Chikaraishi T; Takahashi K; Uchida K; Akiyama T; Tanabe K; Toma H; Exp Clin Transplant; 2016 Oct; 14(5):518-525. PubMed ID: 27733107 [TBL] [Abstract][Full Text] [Related]